Therapeutics Acquisition Corp. (RACA) Shareholders Approve POINT Biopharma Deal
by Marlena Haddad on 2021-06-30 at 6:45am

Therapeutics Acquisition Corp.  (NASDAQ:RACA) announced in an 8-K filing this morning that its shareholders approved its combination with radiopharmaceutical firm POINT Biopharma at a special meeting yesterday.

A not-insignificant number of shareholders opted to redeem their shares in connection with the vote, however. A total of 1,394,131 shares were redeemed, removing $13,941,310 from Therapeutic’s trust, or just over 10%. This is still not a bad result in the current market and should not interfere with the closing of the transaction, expected to come shortly. POINT is expected to trade on the Nasdaq under the symbol “PNT” following close.

Therapeutics initially announced the $639 million deal with POINT Biopharma on March 15. POINT is a clinical stage radiopharmaceutical firm researching the use of radioglands to treat cancer before and during chemotherapy.  POINT is ahead in its development timeline than many other biotech firms targeted by SPACs over the last six months as it already has two cancer therapies in Phase III trials with two more at preclinical stages.

All measures on Therapeutic’s ballot passed by wide margins, but for a full list of proposals and vote tallies, click HERE.


ADVISORS

  • Perella Weinberg Partners LP is acting as lead financial and capital markets advisor to POINT.
  • Cowen and Company, LLC and Piper Sandler are also acting as capital markets advisors to POINT.
  • Jefferies LLC is acting as lead financial and capital markets advisor to RACA.
  • Bass, Berry & Sims PLC is acting as lead legal counsel to POINT.
  • Goodwin Procter LLP is acting as lead legal counsel to RACA.
Therapeutics Acquisition Corp. (RACA) Shareholders Approve POINT Biopharma Deal
Recent Posts
by Nicholas Alan Clayton on 2025-07-02 at 12:13pm

McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...

by Nicholas Alan Clayton on 2025-07-02 at 8:29am

At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....

by Nicholas Alan Clayton on 2025-07-02 at 6:28am

EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...

by Nicholas Alan Clayton on 2025-07-01 at 7:51pm

Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....

by Nicholas Alan Clayton on 2025-07-01 at 7:47pm

Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved